Effect And Safety Of Bioresorbable Scaffold In The Treatment Of STEMI

Objective: We compared the one-year follow-up of efficacy and safety of bioresorbable NeoVas^TM coronary scaffold and Firebird2^TM drug-eluting stent implantation in STEMI patients with single vessel disease who underwent PCI,to provide evidence-based support for the optimization of PCI treatment and the selection of stents.Methods: NeoVas^TM test group consists of a total of 34 acute ST segment elevation myocardial infarction（STEMI）cases with single vessel lesions who underwent PCI with implantation of NeoVas BRS in November 2019 to March2020,which were consistent with the inclusive criterions while failing to meet the exclusive criterions.At the same time,41 cases in accordance with the above set of conditions and exclusion undergoing Firebird2^TM metal drug-eluting stents were assigned to the control group.All cases were followed up for 1 year in outpatients after which the patients were told to return to the hospital for review of coronary angiography.All the text information,collection,the results of the blood test,video data as well as follow-up information were fully collected at the time of admission,discharge and1-year-follow-up.Through the analysis of the above information,the incidence rate of cases of cardiovascular adverse events between the groups（malignant arrhythmia,recurrence of angina pectoris,cardiac death,etc.）were compared and evaluated.The changes of relevant biochemical parameters（serum creatinine,platelet count,white blood cell count,etc.）were observed 1 year after the implantation of Neovas^TMBRS.Results:（1）Patients in the NeoVas^TM scaffold group and the Firebird2^TMstent group had no intraoperative complications such as coronary perforation,or stent detachment.（2）During the follow-up period,no adverse cardiovascular events（malignant arrhythmias,thrombosis,etc.）occurred in the included samples,and there was no significant difference in the incidence of stent restenosis,heart failure,myocardial enzyme abnormality,and recurrent angina pectoris between the groups（P>0.05）.（3）The postoperative ST segment（immediate,24 h,5d）drop rate showed no difference between groups,P>0.05;Comparison of left ventricular ejection fraction（1 year after PCI）and diastolic end-diameter showed that there was no significant difference between the two groups,P>0.05.（4）There were no statistically significant differences in rate of myocardial enzyme abnormity,transaminase,platelet count,red（white）cell count and serum creatinine incidence（1 year after implantation）.Conclusion:There is no significant difference in efficacy or safety between NeoVas^TM group and Firebird 2^TM group in one year follow-up in STEMI cases with single vessel lesions.